vasopharm Completes Patient Enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)

Top-line results expected end of 2020 WÜRZBURG, Germany, Jan. 29, 2020 -- (Healthcare Sales & Marketing Network) -- vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular dise... Biopharmaceuticals, Neurology vasopharm, ronopternin, traumatic brain injury
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news